# EDGAR Filing Document

**Accession Number:** 0001131343
**File Stem:** 0001213900-25-109539
**Filing Date:** 2025-11
**Character Count:** 6496
**Document Hash:** ff4008f730c7aa1a84b7bd84149192ce
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-109539.hdr.sgml**: 20251113

**ACCESSION NUMBER**: 0001213900-25-109539

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20251113

**FILED AS OF DATE**: 20251113

**DATE AS OF CHANGE**: 20251113

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALTERITY THERAPEUTICS LTD
- **CENTRAL INDEX KEY:** 0001131343
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-49843
- **FILM NUMBER:** 251475277

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** LEVEL 3, 460 BOURKE STREET
- **CITY:** MELBOURNE
- **PROVINCE COUNTRY:** C3
- **BUSINESS PHONE:** 61 3 9349 4906

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** LEVEL 3, 460 BOURKE STREET
- **CITY:** MELBOURNE
- **PROVINCE COUNTRY:** C3

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRANA BIOTECHNOLOGY LTD
- **DATE OF NAME CHANGE:** 20010105

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-163**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of November 13, 2025**

**Alterity Therapeutics Limited**

(Name of Registrant)

**Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia**

(Address of Principal Executive Office)

**Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.**

Form 20-F ☒ Form 40-F ☐

**This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. [333-251073](http://www.sec.gov/Archives/edgar/data/1131343/000121390020040485/ea130838-s8_alteritytherape.htm), [333-248980](http://www.sec.gov/Archives/edgar/data/1131343/000121390020027969/ea127207-s8_alteritytherap.htm) and [333-228671](http://www.sec.gov/Archives/edgar/data/1131343/000114420418063081/tv508429_s-8.htm)) and our Registration Statements on Form F-3 (Files No. [333-274816](http://www.sec.gov/Archives/edgar/data/1131343/000101376223000033/ea185947-f3_alteritytherape.htm), [333-251647](http://www.sec.gov/Archives/edgar/data/1131343/000121390020044324/ea132148-f3_alteritytherape.htm), [333-231417](http://www.sec.gov/Archives/edgar/data/1131343/000114420419025615/tv521271_f3.htm) and [333-250076](http://www.sec.gov/Archives/edgar/data/1131343/000121390020036934/ea129831-f3_alteritytherap.htm))**

**ALTERITY THERAPEUTICS LIMITED**

**(a development stage enterprise)**

The following exhibits are submitted:

99.1 [Disclosure under Takeovers Panel GN 20](ea026545901ex99-1_alterity.htm)

**<u>SIGNATURE</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **Alterity Therapeutics Limited** | **Alterity Therapeutics Limited** |
| By: | /s/ Geoffrey P. Kempler |
|  | Geoffrey P. Kempler |
|  | Chairman |

---

Date: November 13, 2025

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

---

| | |
|:---|:---|
| **ASX ANNOUNCEMENT** | 13 November 2025 |

---

**Disclosure under Takeovers Panel Guidance**

**Note 20: Equity Derivatives**

Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) ("the Company") advises that it has received the attached notice from Regal Funds Management Asia Pte Limited which was provided to the Company pursuant to the Australian Takeovers Panel Guidance Note 20 – Equity Derivatives.

Authorised for release by:

Abby Macnish Niven

*Company Secretary*

Alterity Therapeutics Limited

For further information please contact:

**Investors**

Remy Bernarda

Investor Relations Advisory Solutions

<u>ir@alteritytx.com</u>

+1 (415) 203-6386

Alterity Therapeutics Limited ACN 080 699 065

Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia

www.alteritytherapeutics.com

![](ex99-1_002.jpg)

12-November-2025

Dear Alterity Therapeutics ltd,

**Disclosure of Long Equity Derivative Positions**

We refer to Guidance Note 20: Equity Derivatives (**GN20**), issued by the Australian Takeovers Panel. Terms not defined in this notice have the meanings given to them in GN20.

GN20 relevantly provides that the non-disclosure of long positions, including long equity derivative positions, may give rise to unacceptable circumstances. Regal Funds Management Asia Pte Limited, as investment manager of Amazon Market Neutral Fund and Zambezi Absolute Return Fund (the **Funds**), discloses the following information on behalf of the Funds.

---

| | | |
|:---|:---|:---|
| Identity of the taker: | Amazon Market Neutral Fund | Zambezi Absolute Return Fund |
| Relevant security: | Ordinary shares in Alterity Therapeutics ltd | Ordinary shares in Alterity Therapeutics ltd |
| Price (including reference price, strike price, option price etc as appropriate): | Not applicable | Not applicable |
| Entry date and number of securities to which the derivative relates: | Total number of securities to which derivatives relate as at 10-Nov-2025: 50,000,000 (0.46%) | Total number of securities to which derivatives relate as at 10-Nov-2025: 503,141,403 (4.63%) |
| Any material changes to information previously disclosed: | No information previously disclosed | Previous disclosure of below 5% on 31-Jul-2024 |
| Relevant interests in securities: |  |  |
| Long equity derivative positions and relevant interests held by the taker and its associates: | The Funds have no other associates with a long equity derivative position or relevant interest in the company | The Funds have no other associates with a long equity derivative position or relevant interest in the company |
| Short equity derivative positions that offset physical positions: |  |  |
| Short positions of more than 1% that have been acquired after a long position is disclosed, whether by notice or substantial holding notice: |  |  |

---

Yours sincerely

---

| |
|:---|
| /s/ Greg Laughlin |
| Greg Laughlin |

---

Chief Executive Officer

**Regal Funds Management Asia Pte Limited**

Regal Funds Management Asia Pte Limited T +65 6654 1755 80 Raffles Place #26-23 UOB Plaza 2<br> Singapore 048624